391 related articles for article (PubMed ID: 26172282)
1. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
Ng CM; Dombrowsky E; Lin H; Erlich ME; Moody DE; Barrett JS; Kraft WK
Pharmacotherapy; 2015 Jul; 35(7):670-80. PubMed ID: 26172282
[TBL] [Abstract][Full Text] [Related]
2. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
Moore JN; Gastonguay MR; Ng CM; Adeniyi-Jones SC; Moody DE; Fang WB; Ehrlich ME; Kraft WK
Clin Pharmacol Ther; 2018 Jun; 103(6):1029-1037. PubMed ID: 29516490
[TBL] [Abstract][Full Text] [Related]
3. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.
Kraft WK; Gibson E; Dysart K; Damle VS; Larusso JL; Greenspan JS; Moody DE; Kaltenbach K; Ehrlich ME
Pediatrics; 2008 Sep; 122(3):e601-7. PubMed ID: 18694901
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
Jones HE; Johnson RE; Jasinski DR; O'Grady KE; Chisholm CA; Choo RE; Crocetti M; Dudas R; Harrow C; Huestis MA; Jansson LM; Lantz M; Lester BM; Milio L
Drug Alcohol Depend; 2005 Jul; 79(1):1-10. PubMed ID: 15943939
[TBL] [Abstract][Full Text] [Related]
5. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.
Gaalema DE; Heil SH; Badger GJ; Metayer JS; Johnston AM
Drug Alcohol Depend; 2013 Nov; 133(1):266-9. PubMed ID: 23845658
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
7. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Kraft WK; Dysart K; Greenspan JS; Gibson E; Kaltenbach K; Ehrlich ME
Addiction; 2011 Mar; 106(3):574-80. PubMed ID: 20925688
[TBL] [Abstract][Full Text] [Related]
8. A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome.
Hall ES; Isemann BT; Wexelblatt SL; Meinzen-Derr J; Wiles JR; Harvey S; Akinbi HT
J Pediatr; 2016 Mar; 170():39-44.e1. PubMed ID: 26703873
[TBL] [Abstract][Full Text] [Related]
9. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
[TBL] [Abstract][Full Text] [Related]
10. Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
Ebner N; Rohrmeister K; Winklbaur B; Baewert A; Jagsch R; Peternell A; Thau K; Fischer G
Drug Alcohol Depend; 2007 Mar; 87(2-3):131-8. PubMed ID: 17000060
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium.
Liu T; Lewis T; Gauda E; Gobburu J; Ivaturi V
J Clin Pharmacol; 2016 Aug; 56(8):1009-18. PubMed ID: 26712409
[TBL] [Abstract][Full Text] [Related]
12. Breastfeeding promotion for management of neonatal abstinence syndrome.
Pritham UA
J Obstet Gynecol Neonatal Nurs; 2013; 42(5):517-26. PubMed ID: 24020477
[TBL] [Abstract][Full Text] [Related]
13. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.
Jones HE; Dengler E; Garrison A; O'Grady KE; Seashore C; Horton E; Andringa K; Jansson LM; Thorp J
Drug Alcohol Depend; 2014 Jan; 134():414-417. PubMed ID: 24290979
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
Debelak K; Morrone WR; O'Grady KE; Jones HE
Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids.
Hall ES; Rice WR; Folger AT; Wexelblatt SL
Am J Perinatol; 2018 Mar; 35(4):405-412. PubMed ID: 29112997
[TBL] [Abstract][Full Text] [Related]
16. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.
O'Connor AB; Collett A; Alto WA; O'Brien LM
J Midwifery Womens Health; 2013; 58(4):383-8. PubMed ID: 23931660
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.
Kraft WK; Adeniyi-Jones SC; Chervoneva I; Greenspan JS; Abatemarco D; Kaltenbach K; Ehrlich ME
N Engl J Med; 2017 Jun; 376(24):2341-2348. PubMed ID: 28468518
[TBL] [Abstract][Full Text] [Related]
18. Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.
McPhail BT; Emoto C; Fukuda T; Butler D; Wiles JR; Akinbi H; Vinks AA
J Clin Pharmacol; 2020 Apr; 60(4):453-465. PubMed ID: 31820437
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine in Neonatal Abstinence Syndrome.
Kraft WK
Clin Pharmacol Ther; 2018 Jan; 103(1):112-119. PubMed ID: 29105752
[TBL] [Abstract][Full Text] [Related]
20. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
